Thursday, November 5, 2026
ExploreSearch
Via News
Via News Knowledge File

Coinbase Global

organization80% conf.·synced Jul 5, 2026

Largest US-based crypto exchange with jump in Q3 profit from trading volume

44
sourced metrics
179
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week Low
141.09USD
Aug 11, 2026reference only
Price 52 Week High
387.27USD
Aug 11, 2026reference only
Stock Return Ytd
-37.2%
Aug 11, 2026reference only
Stock Price
148.58USD
Aug 11, 2026reference only
Stock Return 1yr
-26.7percent
May 17, 2026source
Net Income
-394USD
May 14, 2026source
Cash
376USD
Apr 28, 2026source
Market Share
9200000monthly_transacting_users
Apr 28, 2026source
Portfolio Weighting
4.32percent
Apr 2, 2026source
Stock Decline From Ath
-60percent
Mar 31, 2026source
Stock Return Since Ipo
-47.2percent
Mar 29, 2026source
Daily Return
4percent
Mar 3, 2026source
Revenue
710-790million_USD
Feb 12, 2026⚠ sources conflictsource
Transaction Revenue
983million_USD
Feb 12, 2026⚠ sources conflictsource
Subscription Services Revenue
710-790million_USD
Feb 12, 2026⚠ sources conflictsource

Stated objectives

Q4 subscription and services revenue expectation

source
target: $710M-$790M by 2025-12-31 00:00:00stated

Q4 subscription and services revenue guidance

source
target: $710-790 million by 2025-12-31 00:00:00stated

Coinbase Q1 2026 subscription and services revenue guidance of $550 million to $630 million

source
target: 550-630 million USD stated

Achieve Q1 2026 subscription and services revenue of $550 million to $630 million

source
target: 550-630 million USD by 2026-03-31 00:00:00stated

Achieve Q1 2026 subscription and services revenue of $550M-$630M

source
target: 550-630 million USD stated

Coinbase Q1 2026 subscription and services revenue guidance

source
target: $550M to $630M stated

Coinbase expects Q1 2026 subscription and services revenue of $550 million to $630 million

source
target: $550M-$630M stated

Q1 2026 revenue guidance

source
target: $550-630 million stated

Coinbase expects subscription and services revenue of $550M to $630M for Q1 2026

source
target: 550 to 630 million USD stated

Reclaim $168-$170 support level where Parabolic SAR sits, then work toward $190 Supertrend level

source
target: 190 stated

Relationship graph · 179 connections

Competes with
32
Covered by
18
Developed by
16
Employs
16
regulates
16
located in
13
Customer of
8
Invested in
8
listed on
NASDAQ →
partnership
Fannie Mae

Via News coverage

Nikkei 225 Slides By 5% In The Last 21 Sessions
April 30, 2024
Coinbase Stock Jump On Monday, Outperforms Market
March 25, 2024
Coinbase Stock Impressive Jump On Wednesday, Outperforms Market
March 20, 2024
Canaan And Signet Jewelers Limited On The List Of Winners And Losers Of Wednesday's US Session
March 20, 2024
Century Communities And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity
March 14, 2024
American Public Education And Xerox Corporation On The List Of Winners And Losers Of Wednesday's US Session
March 6, 2024
Coinbase Stock Was Up By 13.74% Today
March 4, 2024
Coinbase Stock Was Up By 17.13% Today
February 26, 2024
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com